STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

Article excerpt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. As you go about your day today, may you have the confidence of Bryan Johnson and the self-awareness of Elizabeth Holmes (or whoever is behind Holmes’ X account). Lilly granted one person extraordinary access to its next-gen drug Eli Lilly and the FDA have allowed one person to receive the pharma company’s highly promising obesity candidate through the agency’s “compassionate use” program, my colleague Lizzy Lawrence exclusively reports. Continue to STAT+ to read the full story…